Chemomab Therapeutics Ltd. (CMMB)
$0.92
-0.13 (-12.38%)
Rating:
Recommendation:
-
| Symbol | CMMB |
|---|---|
| Price | $0.92 |
| Beta | -0.241 |
| Volume Avg. | 0.06M |
| Market Cap | 10.875M |
| Shares () | - |
| 52 Week Range | 0.901-5.35 |
| 1y Target Est | - |
| DCF Unlevered | CMMB DCF -> | |
|---|---|---|
| DCF Levered | CMMB LDCF -> | |
| ROE | -101.88% | Strong Sell |
| ROA | -115.47% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 0.64% | Neutral |
| P/E | -0.32 | Neutral |
| P/B | 0.46 | Neutral |
Latest CMMB news
About
Download (Excel)Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.